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Meta-analyses of randomized and cohort cell therapy studies have reported that intracoronary or intramyocardial cell 
delivery was safe, and it provided 2% to 8% increases in global 
left ventricular (LV) ejection fraction (EF) in patients with acute 
myocardial infarction (AMI) or ischemic cardiomyopathy.1–4 
Those meta-analyses were based on information from published 
articles and included different patient populations, follow-up 
times, and outcome measures, resulting in data heterogeneity 
because of inconsistent clinical definitions and parameters. In 
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Rationale: The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared collaborative 
multinational database, including individual data of patients with ischemic heart disease treated with cell therapy.
Objective: We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarction (AMI), 
including individual patient data from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, CADUCEUS, 
FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE-TIME; n=1252).
Methods and Results: The primary end point was freedom from combined major adverse cardiac and 
cerebrovascular events (including all-cause death, AMI recurrance, stroke, and target vessel revascularization). 
The secondary end point was freedom from hard clinical end points (death, AMI recurrence, or stroke), assessed 
with random-effects meta-analyses and Cox regressions for interactions. Secondary efficacy end points included 
changes in end-diastolic volume, end-systolic volume, and ejection fraction, analyzed with random-effects meta-
analyses and ANCOVA. We reported weighted mean differences between cell therapy and control groups. No 
effect of cell therapy on major adverse cardiac and cerebrovascular events (14.0% versus 16.3%; hazard ratio, 
0.86; 95% confidence interval, 0.63–1.18) or death (1.4% versus 2.1%) or death/AMI recurrence/stroke (2.9% 
versus 4.7%) was identified in comparison with controls. No changes in ejection fraction (mean difference: 0.96%; 
95% confidence interval, −0.2 to 2.1), end-diastolic volume, or systolic volume were observed compared with 
controls. These results were not influenced by anterior AMI location, reduced baseline ejection fraction, or the use 
of MRI for assessing left ventricular parameters.
Conclusions: This meta-analysis of individual patient data from randomized trials in patients with recent AMI revealed 
that intracoronary cell therapy provided no benefit, in terms of clinical events or changes in left ventricular function.
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Nonstandard Abbreviations and Acronyms
ACCRUE meta-Analysis of Cell-based CaRdiac stUdiEs
AMI acute myocardial infarction
CI confidence interval
CK creatine kinase
EDV end-diastolic volume
EF ejection fraction
ESV end-systolic volume
IHD ischemic heart disease
IPD individual patient data
LV left ventricular
MACCE major adverse cardiac and cerebrovascular events
TVR target vessel revascularization
addition, publication-based meta-analyses may include studies 
that were later withdrawn or that contained publication errors,5 
and they may exclude important trials that reported median val-
ues of skewed data. In contrast, individual patient data (IPD)-
based meta-analyses contain transparent, controlled data, with 
unique definitions; this approach allows analyses of specific sub-
groups and generation of prognostic models.
The largest previous relevant meta-analysis enrolled 50 
studies (n=2625 patients). They reported that cardiac trans-
plantation of adult bone marrow–derived cells provided 
persistent benefits, in terms of clinical outcome and LV pa-
rameters.3 However, a recent meta-analysis on intracoronary 
cell treatment trials, which included 30 studies (n=2037 pa-
tients), could not confirm data obtained from MRI measure-
ments of LV function4; moreover, they were the first to report 
that cell therapy had no effect on clinical outcome. Both meta-
analyses used aggregated data from published studies with 
considerable heterogeneity across the trials involved.
The ongoing meta-Analysis of Cell-based CaRdiac study 
(ACCRUE; NCT01098591, formerly MEta-analysis of Stem 
cell Studies, MESS) is a collaborative, multinational database 
that comprises IPD from randomized and cohort studies. The 
ACCRUE database was established to facilitate exploration of 
the clinical safety and efficacy of cell therapy in patients with 
ischemic heart disease (IHD) and to identify subgroups of pa-
tients predicted to benefit from cell therapy. The present study 
represents the first IPD-based meta-analysis of cell treatment 
in IHD to date. The objectives of the ACCRUE database are 
as follows:
1. To estimate the overall treatment effect of cardiac cell-
based therapy on clinical outcomes, including occur-
rence of major adverse cardiac and cerebrovascular 
events (MACCE, composite of all-cause death, AMI 
recurrence, coronary target vessel revascularization 
[TVR], and stroke) and the occurrence of clinical hard 
end points (death, AMI recurrence, or stroke);
2. To analyze the effect of cell treatment on LV function 
and remodeling, including changes in end-diastolic vol-
ume (EDV), end-systolic volume (ESV), and EF;
3. To identify predictors of MACCE and of LV function 
and remodeling improvements in patients with IHD 
treated with cell therapy;
4. To explore the influence of patient characteristics, in-
cluding cardiovascular risk factors, on the safety and ef-
ficacy of cardiac cell therapy;
5. To identify the characteristics of individual patients with 
IHD, that can predict benefit from cell therapy.
Methods
The main objective of the ACCRUE group is to use IPD to im-
prove the quality of data used in meta-analyses of cell therapy 
studies in patients with chronic IHD and AMI. The first collabora-
tive meeting was held in Vienna, 2007, with the investigators of the 
ASTAMI, REGENT, BOOST, Aalst (Bartunek)-study, BONAMI, 
REPAIR-AMI, Atsma-study, MYSTAR, STEMMI, the Hamburg and 
Novosibirsk intramyocardial studies, and the EUROINJECT-ONE 
cardiac gene therapy study. The meeting aimed to define objectives, 
to establish data contribution criteria, and to appoint the Independent 
Data Committee and Steering Committee (Online Data Supplement).
Criteria for Considering Studies for Inclusion in the 
ACCRUE Database
The criteria for participation in the ACCRUE database were that the data 
must be from randomized or cohort clinical studies, and that cardiac 
regeneration was induced by percutaneous administration of cells or 
cell-based products, or by mobilization of bone marrow–derived cells. 
A continuous literature search was initiated, and principal investigators 
and study coordinators of recently published studies were prospectively 
invited to contribute IPD to the database. Additional study inclusion cri-
teria for randomized studies are included in the Online Data Supplement.
Outcome Measures
The primary outcome measure of the ACCRUE meta-analysis was 
the safety of the treatment, defined as the freedom from MACCE (the 
composite of all-cause death, AMI recurrence, stroke, and TVR). The 
secondary end points were freedom from the combined hard clinical 
end points (all-cause death, AMI recurrence, or stroke) or freedom 
from the individual components of MACCE. Another secondary end 
point was efficacy, defined as changes in LV EDV, ESV, and EF, com-
pared with baseline.
Search Methods for Identifying Studies
Studies were prospectively identified in literature searches, and the 
identified investigators were invited to participate. The search meth-
ods are included in the Online Data Supplement.
Data Collection and Management
The data collection method is described in the Online Data 
Supplement. The corresponding authors and primary investigators 
of the selected studies were e-mailed or contacted personally sev-
eral times with invitations to contribute original data to the central 
database (Figure 1). A database with predefined terms and condi-
tions (determined and agreed on at the first investigator meeting) was 
sent to the participants for depositing the individual data. Authors 
from 39 centers responded, and data were received from 23 cen-
ters6–17 (References 18–28 in the Online Data Supplement). One cen-
ter later cancelled participation and withdrew their data, referencing 
changes in institutional policy. The current ACCRUE database com-
prises 1871 IPD sets from 28 studies (15 randomized and 10 cohort 
cell therapy and 3 granulocyte-colony stimulating factor studies). 
All patients were classified as “cell-treated” (n=1203) or “control” 
(n=668).
In accordance with prespecified plans, analyses performed in 
ACCRUE differ from those performed in the individual papers. 
Therefore, results from the ACCRUE report may be different from 
those reported in the individual papers, particularly when differ-
ent terms were used for event classifications or follow-up times. 
These issues were discussed with the corresponding authors of all 
papers.
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All studies were approved by the local ethics committees. 
Additional approval was obtained for the meta-analysis. Data 
quality was evaluated with quality checklists from CONSORT18 
and PRISMA (http://www.prisma-statement.org) statements and 
guidelines.
The database was controlled by the IDC. It was temporar-
ily closed in June 2014, to perform the first statistical analysis. The 
current meta-analysis included data from patients with recent AMIs 
who were randomized to either intracoronary cell therapy or con-
trol groups (ASTAMI, Aalst, BONAMI, BOOST, CADUCEUS, 
FINCELL, LATE-TIME, REGENT, REPAIR-AMI, SWISS-AMI, 
TIME, SCAMI trials).6–17 The present analysis excluded all noncon-
trolled studies, the MYSTAR study with a combined delivery mode, 
and all randomized percutaneous intramyocardial cell-based studies 
in patients with chronic IHD (Figure 1).
Assessment of Risk of Bias in Included Studies
Methods for assessing the risk of bias and quality assessment are de-
scribed in the Online Data Supplement.
Statistics
This IPD meta-analysis was conducted in accordance with the 
Cochrane Handbook for Systematic Reviews of Intervention19 and the 
guidelines for meta-analysis of IPD for time-to-event outcomes.20,21 
Heterogeneity between the studies was tested with I2 statistics. 
Additional sensitivity analyses were performed to detect differences 
between studies. Two investigators conducted the analyses (E.N., 
M.G.).
Investigation of Heterogeneity and Selection Bias
The statistics for investigating heterogeneity and selection bias of the 
included trials are presented in the Online Data Supplement.
General Statistics
Normally distributed, continuous variables are presented as mean±SD. 
Continuous parameters with skewed distributions are expressed as the 
median and first interquartile range. Binary and categorical variables 
are given as frequencies and percentages. Associations between the 
number of cells/log number of cells and the changes in EDV, ESV, 
or EF in the cell-treated group were calculated with linear regression 
analysis.
All P values were based on 2-sided tests. For multiple compari-
sons, P values <0.01 were considered statistically significant.
IPD Meta-Analysis
All analyses were based on the intention to treat. Multiple Cox regression 
models were used to analyze the primary outcome, stratified for the indi-
vidual studies. The multiple models included cardiovascular prognostic 
factors for the occurrence of MACCE, such as sex, age, diabetes melli-
tus, hypertension, hyperlipidemia, and baseline EDV and EF values. This 
Table 1. Study Characteristics
Name of Study
Sample size (Cell 
Therapy/Controls)
Mean Follow-Up 
Duration, mo Cell Type Location of AMI
Time From AMI to Cell 
Delivery, d Imaging Modality
CADUCEUS 17/8 12 Cardiosphere-derived 
cells
Anterior (except 1) 62±11 MRI
BONAMI 52/49 3 BM-MNC Anterior 9±2 SPECT, RNV
Aalst Study 19/16 4 BM-MNC Multiple 12±1 LV angiography
REPAIR-AMI 101/103 4 BM-MNC Multiple 4±1 LV angiography
BOOST 30/30 6 BM-MNC Multiple 5±1 MRI
LATE-TIME 58/29 6 BM-MNC Multiple 17±5 MRI
ASTAMI 50/50 6 BM-MNC Anterior 6±1 SPECT, 
echocardiography
REGENT 160/40 6 BM-MNC, or selected 
CD34+CXCR
Anterior 7±2 MRI
SWISS-AMI 133/67 4 BM-MNC Multiple 13±10 MRI
TIME 79/41 6 BM-MNC Multiple 5±2 MRI
SCAMI 29/13 12 BM-MNC Multiple 6±1 MRI
FINCELL 39/39 6 BM-MNC Multiple 3±1 Echocardiography
AMI indicates acute myocardial infarction; BM-MNC, bone marrow mononuclear cells; LV, left ventricular; RNV: radionuclide ventriculography; and SPECT, single 
photon emission computed tomography.
Figure 1. Flow diagram of the meta-Analysis of Cell-based 
CaRdiac stUdiEs (ACCRUE) database and participating 
studies. AMI indicates acute myocardial infarction; G-CSF: 
granulocyte colony-stimulating factor; iCMP: ischemic 
cardiomyopathy; and IPD, individual patient data.
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model was used to determine an adjusted, common treatment effect, with 
baseline hazards that varied across studies.20,21 To evaluate possible de-
pendencies of the treatment effect on other prognostic factors, all possible 
interactions were tested within the multiple stratified Cox regression mod-
els. Factors were excluded from the analysis when data were missing in 
≥50% of cases (eg, positive family anamnesis for heart disease, baseline 
infarct size). Adjusted hazard ratios and their 95% confidence intervals 
(CIs) are presented with the corresponding P values. The Kaplan–Meier 
method and cumulative hazards were used to display the MACCE-free, 
death-free, death/AMI recurrence/stroke-free, and TVR-free survival 
rates. Prespecified subgroup analyses for the primary end point and the 
secondary end point of death/AMI recurrence/stroke were performed for 
the following subgroup categories: age (> or ≤57 years), EF (> or ≤45%), 
baseline EDV (> or ≤130 mL), anterior AMI (yes or no), maximal creatine 
Table 2. Baseline Data of Patients With Recent Acute Myocardial Infarction and Randomized to Cell Therapy or Control
Cell Therapy (n=767) Control (n=485) P Value
Baseline
  Age, y 57.3±10.4 57.0±10.7 0.600
  Men 614/767 (80.1%) 405/485 (83.5%) 0.136
  Diabetes mellitus 111/767 (14.5%) 79/485 (16.3%) 0.419
  Hypertension 384/767 (50.1%) 244/485 (50.3%) 0.954
  Hyperlipidemia 387/717 (54.0%) 228/435 (52.4%) 0.626
  Active smoker 396/708 (55.9%) 243/422 (57.6%) 0.620
  Maximal creatine kinase, U/L 3467±2492 3410±2426 0.235
  Number of diseased vessels 1.3±0.6 1.3±0.6 0.952
  Anterior AMI 662/767 (86.3%) 415/485 (85.6%) 0.351
Precell therapy
  End-diastolic volume, mL 146±51 139±48 0.012
  End-systolic volume, mL 84±40 77±36 0.004
  Ejection fraction, % 43.7±11.9 45.5±11.8 0.011
  MRI 492/767 (64.1%) 257/485 (53.0%) <0.001
Cell therapy
  Time from AMI to treatment in cell therapy group and randomization/sham intervention in controls, d 8.0±9.7 6.6±10.9 0.202
  Number of cells injected intracoronary (×106) (median and 25% and 75% interquartile ranges) 150 (6, 294)
  Intracoronary injection-related procedural complication, % 14/630 (2.2%)
  In-hospital complication, % 21/631 (3.3%) 21/413 (5.1%) 0.197
AMI indicates acute myocardial infarction.
Table 3. Primary and Secondary End Points
Cell Therapy (n=767) Control (n=485) P Value
Follow-up
  Follow-up time, d 225±112 231±114 0.375
   Median with range (180; 90–365) (180; 90–365)
  MACCE 107/767 (14.0%) 79/485 (16.3%) 0.289
  All-cause death 11/767 (1.4%) 10/485 (2.1%) 0.499
  Target vessel revascularization 87/767 (11.3%) 65/485 (13.4%) 0.287
  Death or AMI recurrence or stroke 22/767 (2.9%) 23/485 (4.7%) 0.088
  Non-serious adverse events 55/680 (6.5%) 40/472 (8.5%) 0.206
  End-diastolic volume, mL 162±57 153±54 0.008
  End-systolic volume, mL 89±48 82±44 0.012
  Ejection fraction, % 47.3±13.9 48.3±13.4 0.245
Changes from baseline to follow-up (n=624) (n=440)
  ΔEnd-diastolic volume, mL 15.0±40.1 13.8±33.4 0.614
   Mean difference (SE), 95% CI 1.2 (2.3), −3.4 to 5.8
  ΔEnd-systolic volume, mL 5.0±32.5 4.6±27.4 0.853
   Mean difference (SE), 95% CI 0.4 (1.9), −3.4 to 4.1
  ΔEjection fraction, % 3.6±9.5 2.6±8.9 0.096
   Mean difference (SE), 95% CI 0.96 (0.58), −0.2 to 2.1
AMI indicates acute myocardial infarction; and MACCE, major adverse cardiac and cerebrovascular events.
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kinase (CK, > or ≤3450 U/L; CK is associated with infarct size; 3450 U/L 
was the median value for all patients), sex, diabetes mellitus, hyperten-
sion, hyperlipidemia, smoking, and use of MRI.
The secondary end points, changes in LV EF, EDV, and ESV, were 
evaluated with ANCOVA. The treatment effect was adjusted for car-
diovascular risk factors, men, mode of measuring LV function, ante-
rior location of AMI, baseline EDV, baseline EF, and time between 
AMI and randomization/sham intervention in controls or cell therapy 
in cell-treated groups; for these adjustments, the individual studies 
were considered a block factor. Possible interacting effects with treat-
ment were tested within these ANCOVA models. Changes in EDV, 
ESV, and EF in the cell therapy and control groups are expressed as 
mean±SD; the mean difference from baseline was reported with SE 
and the relative 95% CIs were reported as effect measures.
Prespecified subgroup analyses included the effect of follow-up 
time and the effect of baseline EF on changes in LV function, evalu-
ated as dichotomous variables. The numbers of patients in groups 
who received different subtypes of autologous cells were uneven or 
low; therefore, we did not perform subgroup analyses on the effect of 
cell types on the end points.
All statistical computations were performed with Review Manager 
5.2 (The Nordic Cochrane Center, Købehvn, Denmark), and Stata/
SE, version 12, for Windows (StataCorp, Houston, TX).
Results
Search Results
A systematic search for eligible trials resulted in 1533 clinical 
reports on cardiac cell therapies. Of these, 921 were excluded 
on the basis of the preclinical nature of the studies or because 
they were only abstracts or incomplete reports. Thus, 612 
clinical studies were eligible, and 149 were selected because 
they used cell injections or autologous bone marrow–derived 
cells mobilization. A further 94 studies were excluded because 
they were reviews, descriptions of surgical approaches, or pi-
lot studies for study designs or subanalyses. Finally, 55 studies 
were selected, and the corresponding authors were contacted. 
The present analysis included 12 randomized studies on intra-
coronary cell therapy applied after AMI (Figure 1).
Study Characteristics
Table 1 lists the study characteristics. An average of 104 pa-
tients were included in the studies (n=64 and n=40 for cell 
treatment and control groups). Most studies used bone mar-
row mononuclear cells, and MRI was used for visualizing 
and quantifying LV performance. Three studies assessed 
the timing of cell therapy (CADUCEUS, LATE-TIME, 
Figure 2. Primary end point analysis. A, Major adverse cardiac and cerebrovascular events (MACCE)-free survival of patients with recent 
acute myocardial infarction who were randomized to either cell therapy or control treatment (top). Hazard ratio and 95% confidence 
intervals (CI) of risk factors that favor cell therapy or control treatment (bottom). MACCE defined as all-cause death, reinfarction, target 
vessel revascularization, and stroke; DM indicates diabetes mellitus; EDV, end-diastolic volume; and EF, ejection fraction. B, Forest plot of 
MACCE-free survival in subgroups, with creatine kinase (CK), CI, hazard ratio (Haz), and P for interaction (P inter).
A
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SWISS-AMI); otherwise cell therapies were performed with-
in 2 weeks post-AMI. Most patients were randomized during 
the first week (65% of patients in the cell therapy and 79% 
of patients in the control group), and EF was measured be-
fore randomization. The quantitative baseline LV functional 
parameters were assessed at the time of the primary percu-
taneous coronary intervention (eg, FINCELL), before ran-
domization, 1 to 3 days post-AMI (eg, REGENT), or several 
weeks post-AMI after resolution of myocardial stunning (eg, 
LATE-TIME). Thus, there were different time lapses between 
the delivery of cell therapy and the measurement of baseline 
LV function.
All patients received clinical follow-ups. Paired LV func-
tional data measured at baseline and at follow-up were avail-
able for 1064 (624 cell therapy and 440 control) patients. 
Baseline LV function and follow-up events were not different 
for patients who lacked paired LV data for any reason (data 
not shown).
Infarct size data were available for 114 of 767 patients 
(14.9%) who received cell therapy and for 111 of 485 patients 
(22.9%) in the control group. Because these groups did not 
represent the entire population, we did not analyze changes 
in infarct size.
Study Quality and Risk of Bias in Included Studies
Online Table I shows the quality assessment scales of the 
studies on randomized intracoronary cell therapy in AMI that 
were included in the ACCRUE database. The internal validity 
scales, the results of the external validity criteria, and sensitiv-
ity analyses are described in Online Data Supplement.
Baseline Patient Characteristics
Table 2 shows the baseline clinical data, including measure-
ments of baseline LV function parameters. No differences 
were observed between the 2 groups with the exception of 
ESV, which was lower in controls. Cardiac MRI was more 
often used as the imaging modality in the cell therapy group 
because of the higher number of patients in cell therapy group 
than in the control groups of the SWISS-AMI and REGENT 
trials (2:1 randomization).
Primary End Point
MACCE was similar between the groups (hazard ratio, 0.86; 
95% CI, 0.63–1.18; Table 3; Online Figure I). After adjust-
ing for all confounding factors, the Cox regression showed 
no effect of cell therapy on MACCE-free survival (Table 3; 
Figure 2). The addition of anterior AMI as a confounding fac-
tor did not influence the primary outcome (Online Table II). 
The subgroup analysis did not reveal a prognostic factor for 
prevention of MACCE (Figure 2); therefore, we found no fac-
tors that influenced the success of cell therapy.
The results of the overall meta-analysis (between-trial 
analysis) for the primary end point were highly consistent in 
direction and magnitude with those obtained from the indi-
vidual participant data meta-analyses (within-trial analyses); 
ie, there was no significant benefit with cell therapy versus 
controls (hazard ratio, 0.86; 95% CI, 0.63–1.18; P=0.884). No 
Figure 2. Continued
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significant heterogeneity or inconsistency was found between 
trials (I2=0%). In addition, the funnel plot for the primary end 
point did not show asymmetry on visual inspection (Online 
Figure I), which was confirmed by a nonsignificant Egger test.
Secondary End Points
Similar to the primary end point, cell therapy did not improve 
clinical outcome in terms of the incidence of death, or death/
AMI recurrence/stroke, and TVR (Table 3; Figure 3A, Online 
Figure II). No cardiovascular risk factor could be identified 
that influenced the clinical hard end points (death/AMI recur-
rence/stroke). Similarly, the hard end points were not impacted 
by a lower baseline EF, a higher EDV, the location of infarc-
tion, the maximal CK, or whether LV function was measured 
with MRI. Although we observed a trend toward differences 
in different subgroups, as shown in the forest plot (Figure 3B), 
no interaction was significant (P>0.01).
Both EDV and EF increased slightly in cell-treated and 
control groups (Table 3) without a decrease in ESV from base-
line to follow-up. Cell therapy did not influence the changes in 
global EF (mean between-group difference of 0.96%; 95% CI, 
−0.2 to 2.1), EDV (1.2 mL; 95% CI, −3.4 to 5.8), or ESV (0.4 
mL; 95% CI, −3.4 to 4.1; Table 3; Figure 4).
Table 4 summarizes the ANCOVA results (detailed data in 
Online Table III). The final changes in EDV, ESV, and EF were 
not influenced when the model included covariates of sex, age, 
diabetes mellitus, hypertension, hyperlipidemia, anterior AMI 
location, MRI imaging modality, baseline EDV, baseline EF, 
or timing of cell treatment. Cell therapy in older patients led 
to a greater increase in EDV compared with controls, with no 
significant changes in ESV or EF (Online Table III).
Subanalysis of Different Follow-Ups
Four studies provided a 1-year clinical follow-up data 
(CADUCEUS, REPAIR-AMI, SWISS-AMI, and SCAMI); 
the other studies reported clinical follow-ups of ≤6 months. 
No difference between the groups was identified at the 
6-month follow-ups or at the 6- to 12-month follow-ups 
on MACCE, death, death/AMI recurrence/stroke, or TVR 
(Online Figures III–V). The majority of MACCE events were 
TVR at the 6-month follow-up. Trials with a planned 6-month 
clinical follow-up controlled the patients and performed TVR 
Figure 3. Secondary end point analysis. A, Kaplan–Meier analysis of death/acute myocardial infarction (AMI)/stroke–free survival of 
patients randomized either to cell therapy or controls (top). Hazard ratio (Haz) and 95% confidence intervals (CI) of risk factors favoring 
cell therapy or control treatment (bottom). DM indicates diabetes mellitus; EDV, end-diastolic volume; and EF, ejection fraction. B, Forest 
plot of death/AMI/stroke-free survival in subgroups with hazard ratio, CI, P for interaction (P inter), and CK, creatine kinase. C, Kaplan–
Meier analysis of target vessel revascularization (TVR)-free survival (top). Hazard ratio and 95% CIs of risk factors favoring cell therapy or 
control treatment (bottom).
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Death / AMI/ Stroke
Favours cell therapy Favours controls
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Ratio
95% CI P value
Type of 
treatment 0.534 0.265 - 1.078 0.08
Gender 1.047 1.01 - 1.086 0.012
DM 1.101 0.46 - 2.635 0.829
Hypertension 1.04 0.46 - 2.352 0.925
Hyperlipidaemia 1.835 0.815 4.135 0.142
Age 0.719 0.352 - 1.471 0.367
Baseline EDV 0.998 0.989 - 1.007 0.673
Baseline EF 0.964 0.932 - 0.996 0.028
Hazard rao 95% CI
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when in-stent restenosis of the infarct-related artery was docu-
mented. This resulted in an increase in the TVR incidence at 6 
months, but there was no difference between groups.
Most of the LV functional measurements were performed 
at the 6-month follow-up; the Aalst-study, BONAMI, and 
REPAIR-AMI provided 3- or 4-month follow-up data; the 
CADUCEUS and SCAMI studies also had control measure-
ments at 1 year. Table 5 shows the follow-up time-dependent 
changes in LV EDV, ESV, and EF in cell-treated and control 
groups. An increase was observed in EDV from baseline to the 
6-month and 12-month follow-ups in both the cell therapy and 
control groups. Because of the relatively low numbers of pa-
tients in these subgroups, and to avoid a type I error, we did not 
perform statistical comparisons between the 6- and 12-month 
follow-up data. No difference between groups was detected on 
follow-up data collected at ≤6 months, or >6 months.
Subanalysis of Baseline EF Effects on Changes in 
LV Parameters
The subclasses of baseline EF (>50%, >45%, and >40%) 
showed no influence of baseline EF on the changes in EDV, 
ESV, or EF at the follow-up (Table 6).
Effect of the Number of Injected Cells  
on LV Function
Linear regression analysis showed no correlation between the 
number of injected cells or the log number of injected cells and 
the changes in EDV, EF (Online Figure VI), or ESV (data not 
shown) in the cell-treated group. There was, however, a large 
scatter in the number of cells applied (range: 12.5–4303×106).
Comparison of ACCRUE Data With Results From 
Nonparticipating Studies
Online Table IV summarizes the results from currently pub-
lished randomized cell-therapy trials in patients with recent 
AMI who did not contribute to the ACCRUE database. The re-
ported mean EF, SD, and the number of included patients are 
shown (References 29–47 in the Online Data Supplement). 
These 19 studies included 503 patients (mean=27) in the 
cell-treated group and 352 patients (mean=19) in the control 
group. In contrast, the ACCRUE intracoronary arm included 
767 patients (mean=64) in the cell-treated group and 485 pa-
tients (mean=40) in the control group. The ACCRUE database 
currently represents >70% of all clinical cardiac regeneration 
Figure 3. Continued
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studies and ≈60% of all intracoronary cell studies; it includes 
all major randomized studies, except the HEBE trial, the Cao, 
and the Chen studies (References 36, 40, and 45 in the Online 
Data Supplement).
Discussion
The ACCRUE is the first IPD database to facilitate meta-anal-
yses of cardiac cell therapy. The database currently comprises 
a pool of 1871 IPD from 15 randomized cardiac regeneration 
studies; 12 of these studies (with 1252 IPD) involved intra-
coronary cell delivery in patients with recent AMIs. This first 
meta-analysis of the ACCRUE selecting these 12 randomized 
studies on intracoronary administration of reparative cells 
shows no effect of cell therapy on clinical events or changes in 
LV function or remodeling. On the basis of original data, we 
could not identify predictive factors or patient characteristics 
that might indicate patients most likely to benefit from cell 
therapy.
An important feature of this ACCRUE, which is rarely seen 
in other meta-analyses, is its prospective nature, following the 
Cochrane guidelines for planning and conducting an IPD me-
ta-analysis. The prospective data collection of ACCRUE al-
lows the uniform definitions of end points, follow-up periods, 
and adverse events; this approach ensured the most unbiased, 
and thus, the most reliable results, and increased the robust-
ness and accuracy of the findings.
However, some caution should be taken with the interpre-
tation of our results. The negative and, for the health com-
munity, disappointing results are not surprising. Six of the 
included studies (including about two thirds of the study pa-
tients), which comprised the largest and most homogeneous 
clinical populations (ASTAMI, BONAMI, REGENT, TIME, 
LATE-TIME, SWISS-AMI), reported no benefit from autolo-
gous cell-based, intracoronary regenerative treatment.8,9,11,15–17 
One of the 3 similarly large studies which were not included 
in the ACCRUE database (HEBE) also reported a negative 
outcome.
Potentially, the efficacy of cell therapy could be affected 
by differences among the studies included in the ACCRUE 
database. For example, differences in the types of injected 
cells and the timing of cell administration (acute phase of AMI 
versus convalescent AMI) may affect the outcomes. We did 
not evaluate these factors separately because the individual 
subgroups would have comprised statistically unacceptably 
low number of patients. However, the ANCOVA analysis 
showed that, when the time to cell/control therapy was con-
sidered as an independent covariate, it did not significantly 
affect the changes in EDV, ESV, or EF. An additional factor 
that might influence changes in LV function could be the time 
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TVR
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Ratio
95% CI P value
Type of 
treatment 0.831 0.565 - 1.222 0.346
Gender 1.01 0.991 - 1.029 0.304
DM 0.985 0.602 - 1.611 0.952
Hypertension 0.871 0.527 - 1.44 0.589
Hyperlipidaemia 1.184 0.786 - 1.783 0.418
Age 1.157 0.774 - 1.73 0.476
Baseline EDV 1.003 0.997 - 1.008 0.332
Baseline EF 1 0.981 - 1.02 0.974
Hazard rao 95% CI
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that baseline EF was measured (if not the same day as the 
cell therapy). This timing may be consequential, considering 
that, in the natural course of the reperfused AMI, during the 
first week, rapid changes were observed in the EF, and the 
size of late enhancement in serial MRI.22 Moreover, there was 
a time-dependent component in the regenerative function of 
the different types of harvested autologous comorbid bone 
marrow–origin cells.23
Adverse Events, LV Function, and LV Remodeling 
Related to Intracoronary Cell Therapy
Intracoronary administration of cells proved to be safe, with 
a low procedural complication rate (2.2%). The composite 
in-hospital complications were similar between groups. The 
mortality and incidence of hard clinical end points were no-
ticeably low among the patients with ST-segment–elevation 
myocardial infarction in both groups. This finding may have 
Figure 4. Forest plot displaying changes in left ventricular ejection fraction, end-diastolic and end-systolic volumes in patients 
treated with intracoronary cell therapy after recent acute myocardial infarction. Unadjusted difference in mean with 95% confidence 
intervals (CI). A, Forest plot of changes in ejection fraction. B, Forest plot of changes in end-diastolic volumes. C, Forest plot of changes 
in end-systolic volumes.
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resulted from the carefully selected patients and the rela-
tively high baseline EFs. Subanalyses of different follow-
ups did not change the outcome difference between treated 
and control patients; the negative results were consistent. We 
point out that a placebo effect has been observed in blinded 
randomized trials, although this effect might be less signifi-
cant than in nonrandomized studies. Because the placebo ef-
fect is additive to the control treatment effect, it can reduce 
Table 4. Results of Interaction Analysis (ANCOVA Models) in Patients With Recent Acute Myocardial 
Infarction and Randomized Either to Cell Treatment of Controls
Changes in EDV Changes in ESV Changes in EF
Cell treatment effect with men
  P value 0.919 0.977 0.091
  Mean difference −0.32 −0.08 1.34
  SE (95% CI) 3.2 (−6.6 to 5.9) 2.6 (−5.2 to 5.1) 0.79 (−0.2 to 2.9)
Cell treatment effect with diabetes mellitus
  P value 0.483 0.694 0.388
  Mean difference 2.30 1.06 0.70
  SE (95% CI) 3.3 (−4.1 to 8.7) 2.7 (−4.2 to 6.3) 0.8 (−0.9 to 2.3)
Cell treatment effect with hypertension
  P value 0.603 0.852 0.092
  Mean difference 1.22 0.36 0.98
  SE (95% CI) 2.3 (−3.4 to 5.8) 1.9 (−3.4 to 4.1) 0.6 (−0.2 to 2.1)
Cell treatment effect with hyperlipidemia
  P value 0.430 0.738 0.067
  Mean difference 1.95 0.67 1.09
  SE (95% CI) 2.5 (−2.9 to 6.8) 2.0 (−3.3 to 4.6) 0.6 (−0.1 to 2.3)
Cell treatment effect with MRI
  P value 0.604 0.887 0.028
  Mean difference 1.26 −0.28 1.31
  SE (95% CI) 2.4 (−3.5 to 6.0) 2.0 (−4.2 to 3.6) 0.6 (0.1 to 2.5)
Cell treatment effect with age
  P value 0.006 0.029 0.702
  Mean difference 9.50 6.46 0.35
  SE (95% CI) 3.4 (−2.8 to 16.2) 2.9 (−0.7 to 12.2) 0.9 (−1.5 to 2.2)
Cell treatment effect with anterior infarction
  P value 0.737 0.448 0.074
  Mean difference −1.11 −2.05 1.47
  SE (95% CI) 3.3 (−7.6 to 5.4) 2.7 (−7.4 to 3.3) 0.8 (−0.1 to 3.1)
Cell treatment effect with pre-end-diastolic 
volume
  P value 0.408 0.867 0.238
  Mean difference 1.46 0.26 0.76
  SE (95% CI) 1.8 (−2.0 to 5.0) 1.5 (−2.8 to 3.3) 0.6 (−0.5 to 2.0)
Cell treatment effect with pre-ejection fraction*
  P value 0.418 0.793 0.304
  Mean difference 1.69 0.51 0.76
  SE (95% CI) 2.1 (−2.4 to 5.8) 1.9 (−3.1 to 4.3) 0.7 (−0.7 to 2.2)
Cell treatment effect with time to cell therapy†
  P value 0.649 0.938 0.435
  Mean difference 7.78 8.92 −0.73
  SE (95% CI) 4.9 (−1.9 to 17.5) 4.0 (1.1–16.8) 1.2 (−1.6 to 3.1)
CI indicates confidence interval; EDV, end-diastolic volume; EF, ejection fraction; and ESV, end-systolic volume.
*Subanalysis between pre-EF groups are displayed in Table 6.
†Effect of the covariate time to cell therapy in cell therapy group or randomization/sham intervention in controls post-AMI.
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the observed treatment effect size and the statistical power 
of the study.
Most patients underwent MRI scanning, which is re-
garded the gold standard for assessing LV function. Similar 
to our results, de Jong et al4 found that the beneficial ef-
fect of cell therapy on LV EF and infarct size disappeared, 
when MRI was used for quantitative imaging. In addition, 
both studies found that the baseline EF did not affect the 
improvement in LV function compared with time.4 Also 
our data were consistent with a previous study, where se-
rial cardiac MRIs of patients with reperfused first AMIs 
showed a gradual increase in LV EDV during the first year 
after the AMI.22
In contrast with previous meta-analyses3,4 we did not assess 
infarct size at follow-up because the majority of trials did not 
measure infarct size before cell therapy; therefore, no change 
between baseline and follow-up could be reported. Instead, 
we added the maximal CK as a confounding factor that could 
influence the outcome because maximal CK is highly associ-
ated with infarct size.24
In contrast with previous meta-analyses, we found no as-
sociation between the number of cells delivered and the out-
comes. It should be mentioned, however, that the numbers 
of cells used for intracoronary cell therapy varied widely, 
even without considering trials that assessed the impor-
tance of cell number on the clinical or functional outcome. 
Table 6. Impact of Baseline Ejection Fraction on Changes in Left Ventricular Parameter
Baseline Ejection 
Fraction
Changes in End-Diastolic 
Volume (Mean±SD)
Changes in End-Systolic 
Volume (Mean±SD)
Changes in Ejection 
Fraction (Mean±SD)
≥50% Cell therapy (n=179) 14.6±35.2 6.3±26.5 2.2±8.3
Controls (n=145) 10.6±29.5 4.0±19.8 0.7±8.7
Difference in mean between cell therapy and 
controls (95% CI)
4.0 (−3.2 to 11.2) 2.2 (−3.0 to 7.5) 1.5 (−0.4 to 3.3)
<50% Cell therapy (n=445) 15.2±42.1 4.5±34.7 4.1±9.9
Controls (n=295) 15.5±35.2 4.9±30.5 3.5±9.0
Difference in mean between cell therapy and 
controls (95% CI)
−0.3 (−6.1 to 5.6) −0.5 (−5.4 to 4.4) 0.6 (−0.8 to 2.0)
≥45% Cell therapy (n=267) 11.1±34.8 4.2±26.5 2.3±9.0
Controls (n=212) 9.7±29.6 2.9±20.8 1.3±8.7
Difference in mean between cell therapy and 
controls (95% CI)
1.4 (−4.5 to 7.39) 1.3 (−3.1 to 5.6) 1.0 (−0.6 to 2.6)
<45% Cell therapy (n=357) 18.1±43.6 5.6±36.4 4.5±9.8
Controls (n=228) 17.9±36.4 6.2±32.4 3.8±9.0
Difference in mean between cell therapy and 
controls (95% CI)
0.2 (−6.7 to 7.1)  −0.6 (−6.5 to 5.2) 0.7 (−0.8 to 2.3)
≥40% Cell therapy (n=381) 12.1±36.8 4.0±27.1 2.6±9.2
Controls (n=292) 10.8±31.0 3.3±22.6 1.9±8.5
Difference in mean between cell therapy and 
controls (95% CI)
1.4 (−3.9 to 6.6) 0.7 (−3.1 to 4.6) 0.8 (−0.6 to 2.2)
<40% Cell therapy (n=243) 19.7±44.7 6.5±39.7 5.0±9.7
Controls (n=148) 202±37.2 7.3±35.1 4.1±9.6
Difference in mean between cell therapy and 
controls (95% CI)
−0.5 (−9.2 to 8.2) −0.8 (−8.7 to 7.1) 0.9 (−1.1 to 2.9)
No significant difference between the groups. CI indicates confidence interval.
Table 5. Efficacy of Cell Therapy Compared With Time
Follow-Up Time Changes in EDV (Mean±SD) Changes in ESV (Mean±SD) Changes in EF (Mean±SD)
≤6 Months Cell therapy (n=383) 10.2±37.3 2.2±32.6 3.9±10.3
Controls (n=267) 8.4±28.8 0.31±26.2 2.9±9.6
Difference in mean (95% CI) 1.9 (−3.4 to 7.2) 1.9 (−2.9 to 6.6) 0.9 (−0.6 to 2.5)
>6–12 Months Cell therapy (n=241) 22.4±43.3 9.3±32.0 3.1±8.1
Controls (n=173) 22.2±37.9 11.3±28.0 2.1±7.8
Difference in mean (95% CI) 2.6 (−7.8 to 8.3) −2.0 (−8.0 to 4.0) 1.0 (−0.6 to 2.5)
No significant difference between the groups. CI indicates confidence interval; EDV, end-diastolic volume; EF, ejection fraction; and ESV, end-systolic 
volume.
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Previous studies reported only the mean or median numbers 
of injected cells/group. Therefore, the results of those analy-
ses should be considered less exact than results from this 
ACCRUE study.
One of the objectives of this meta-analysis was to reveal 
prognostic factors for clinical events or identify patients who 
might benefit from cell therapy. We did not achieve this objec-
tive, despite the fact that intracoronary treatment arm of the 
ACCRUE database included large randomized studies (mean 
of 104 patients per study) with remarkably low between-trial 
heterogeneity, when compared with the previous largest re-
ported meta-analysis.3,4 Because we used common definitions 
of primary end points throughout the studies, the heterogene-
ity for clinical end points was 0% among studies. In contrast to 
previously published meta-analysis, which showed up to 87% 
heterogeneity among studies, our meta-analysis showed little 
or no heterogeneity among studies for continuous parameters 
of the secondary end points, ie, the heterogeneities were 0% 
for ΔEDV, 11% for ΔESV, and 48% for ΔEF. This highlighted 
the accuracy of a large-scale IPD-based meta-analysis in char-
acterizing any potential effect in different clinical subgroups 
and its pivotal role in fully exploring the clinical relevance 
and adequacy of cell therapy for treating IHD. However, ac-
cording to de Jong et al,4 >30 000 patients should be included 
in a study to identify an effect of cell therapy, when mortality 
is ≈2%.
Advantages of the IPD-Based Meta-Analysis
This ACCRUE IPD-based meta-analysis overcame the major 
limitations of systematic reviews and conventional meta-anal-
yses. Those approaches extract aggregated data from available 
publications according to a predefined study protocol, and the 
random effects are determined by calculating the weighted 
means (eg, relative risk) of randomized trials. Accordingly, 
publication-based meta-analyses must exclude some impor-
tant trials, where group differences are expressed as the medi-
an and interquartile range (eg, BONAMI, HEBE, MYSTAR, 
REGENT). Online Table IV shows the heterogeneity among 
reports of LV functional data from studies that were not in-
cluded in the ACCRUE database. All but 1 study (Ruan et al, 
Reference 47, in the Online Data Supplement) were included 
in a recent intracoronary cell therapy AMI meta-analysis.4 
When no original data were available, they recalculated the 
mean differences and 95% CIs or SDs with meta-analysis 
software and a standardized formula. Thus, these recalculated 
data were partially discrepant with the published or original 
data; eg, Plewka et al showed changes in EF from baseline to 
follow-up of 10±9% in the cell therapy group versus 5±8% 
in controls (Reference 35 in the Online Data Supplement); 
in contrast; the calculated random-effect meta-analysis data 
showed EF changes of 9±5.8% versus 5±4.9%, or 9±7% ver-
sus 5±3.4% in cell-treated versus control groups, respective-
ly.3,4 In contrast, the present IPD meta-analysis included raw 
data; thus, we could calculate accurate real means with SDs, 
mean differences with SEs and CIs; moreover, these calcula-
tions were not influenced by the limited information gained 
from the publications.
Limitations of the ACCRUE Database
A major limitation of the presented study was the combina-
tion of several different cell types (bone marrow mononu-
clear cells, CD133+ -enriched bone marrow–derived cells or 
CD34+CXCR selected cells, or cardiosphere-derived cells). 
As in all previous meta-analyses, we assumed that the potency 
was comparable among different cell types. In fact, different 
cell population exert heterogeneous effects, depending on the 
amount of time passed since AMI.23 In addition, when vari-
ous clinically used cell types were compared directly in the 
same mouse infarct model, the rank order of efficacy was car-
diosphere-derived cells>>bone marrow mononuclear cells.25 
Only 2% of the ACCRUE database comprised heart-derived 
cells; thus, heart cells were not well-represented in the pres-
ent analysis. In addition, intracoronary infusion of allogeneic 
mesenchymal stem cells resulted in a 6.28% increase in EF, 
as reported by de Jong et al.4 Our meta-analysis contained 
only studies with autologous cells, which in turn, increased 
its homogeneity.
Another limitation was that the ACCRUE database included 
fewer studies and patients than the total number of available 
published studies. Thus, this study did not include all studies 
that would be typically incorporated into a conventional meta-
analysis. This lack was partly because of the resistance from 
centers to provide individual data, and partly because of the 
temporary closure of the database, which precluded studies 
that were published later.
Most previous large medical IPD-based meta-analysis 
studies were company sponsored. Those studies implement-
ed a generalized electronic case report form, and the database 
and data were monitored by external monitoring companies. 
Therefore, extraction of standardized data from case report 
forms was a priori facilitated. However, to date, no compa-
ny-sponsored studies on cell-based cardiac regeneration with 
intracoronary cell delivery have been conducted and con-
trolled centrally. To date, no financial support was available 
for the effort of providing and formatting data in accordance 
with the ACCRUE database. In addition, data that did not 
represent the entire population could not be assessed, such 
as medication during follow-up, or data on stent thrombosis. 
However, the statistical analysis revealed a remarkably low 
heterogeneity across the trials in this ACCRUE study (I2, 0% 
to 48%), compared with previous, largest meta-analyses (I2, 
up to 87%),3,4 because of the prespecified baseline and out-
come parameters.
The results of this IPD meta-analysis revealed some impor-
tant discrepancies from previous meta-analyses. Our findings 
highlighted the lack of consistent efficacy in cell-based car-
diac regeneration with intracoronary delivery in patients with 
diverse cardiovascular risk factors. Although the ACCRUE 
database continues to recruit data, it cannot replace large-
volume, prospective randomized studies, such as the ongoing 
BAMI trial (ClinicalTrials.gov Identifier: NCT01569178) or 
the CCTRN network.26,27
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What Is Known?
•	 Previous meta-analyses of randomized, cardiac cell-based therapy 
studies have shown moderate, but significant improvements in clini-
cal outcome and left ventricular function.
•	 Those meta-analyses suggested that the beneficial effects were 
gained by increases in the number of cells delivered, by timing cell 
therapy for delivery 5 to 8 days post–myocardial infarction, or by 
selecting patients with decreased ejection fraction.
What New Information Does This Article Contribute?
•	 These meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) rep-
resent the first prospective meta-analysis in this field to be based on 
individual patient data (IPD), rather than on the aggregated data used 
in conventional meta-analyses.
•	 These IPD-based meta-analysis of randomized studies found that 
intracoronary administration of autologous reparative cells had no 
effect on major adverse cardiac and cerebrovascular events or on left 
ventricular performance or remodeling.
•	 Our results were not influenced by the timing of cell therapy, by the 
number of injected cells, or by the baseline cardiac ejection fraction.
This meta-analysis was based on a collaborative, multinational 
database (ACCRUE) that comprised IPD from randomized and co-
hort studies. The ACCRUE database was established to facilitate 
explorations of the clinical safety and efficacy of cell therapy in 
patients with ischemic heart disease and to identify subgroups 
of patients predicted to benefit from cell therapy. The ACCRUE 
database represents the most comprehensive source of evi-
dence available to date. The present prospective study was the 
first to analyze data in the ACCRUE database on patients with 
recent acute myocardial infarctions. We included IPD from 12 
randomized studies, and found that intracoronary autologous cell 
administration provided no benefit on overall clinical outcome. 
Moreover, we found no benefit on left ventricular performance or 
remodeling. Because the data pool comprised IPD, we could ap-
ply prespecified definitions of baseline and outcome parameters 
that accommodated multiple points of view and represented both 
clinical and functional end points. We tested the stability of these 
clinical and quantitative end points in several sensitivity analyses 
and found consistent results. This approach provided robust and 
justified conclusions.
Novelty and Significance 
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SUPPLEMENTAL MATERIAL 
 
Gyöngyösi. IPD meta-analysis of cell studies  
 
Supplemental Methods 
 
The ACCRUE Study is organized as follows: Independent Data Committee: Mariann Gyöngyösi 
(PI), Eliano Navarese (statistician) and Christer Sylven (data monitoring). Steering Committee: 
Wojciech Wojakowski MD, Patricia Lemarchand MD, Jozef Bartunek MD, Jens Kastrup MD and 
Douwe Atsma MD. 
 
Additional study inclusion criteria for randomized studies 
Additional inclusion criteria for the randomized AMI groups in the present analysis were: 
ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary 
intervention, autologous cell-based therapy within 3 months after STEMI, intracoronary delivery of 
cells and a control arm that did not receive cells.  
Due of the complexity of the database and the substantial differences between patients with 
recent AMI or ischemic cardiomyopathy, these two main patient subgroups were analyzed 
separately. 
 
Search methods for identifying studies 
The search methods for identifying studies were previously described in our recent review.1 
Briefly, we performed monthly searches on Medline, Google Scholar and Embase databases, and of 
the www.clinicaltrials.gov homepage for trials and manuscripts published recentl,y with the 
following search terms, alone or in combination: “cardiac stem cell”, “intracoronary stem cell”, 
“myocardial infarction”, “patient”, “percutaneous cell therapy”, and “myocardial ischemia”. 
Published abstracts and full-text articles written in English were reviewed. Studies were excluded 
when they presented only partial results of incomplete studies or meta-analyses2-16 or when they 
presented only the abstract of a study or a sub-analyses of a previous report. Data from abstracts 
were not included, because they reported partial results or sub-analyses.   
 
Data collection and management 
We identified 55 published trials that applied cell therapy to induce cardiac regeneration in patients 
with ischemic heart disease (IHD). Data were extracted and entered on pre-specified forms by 2 
independent investigators (JB, IP), who were not involved in any of the included studies. Internal 
validity was independently appraised by 2 investigators (MG, JB). 
After data collection, the data were checked for inconsistencies, and the corresponding authors 
were contacted to clarify and correct the data. Where appropriate, the longest FUP time was 
chosen, when data were available, even when previous publications had reported shorter FUP time 
results. Data from cardiac MRIs, when available, were used for LV functional diagnosis; otherwise, 
contrast ventriculography, gated single photon emission computed tomography, or transthoracic 
echocardiography was applied. 
When data proved to be compatible, they were transferred into the ACCRUE database. 
 
Risk of bias and quality assessment of the studies 
Data selection was primarily driven by the nature of the therapy, the ability of data to 
adequately fulfill the ACCRUE database objectives, the representativeness of the studies and the 
accessibility to the IPD of the studies. The quality assessment of the studies was performed in 
accordance with the Jüni criteria listing the internal validity parameter of the studies.17  
 
Investigation of heterogeneity and selection bias 
We also performed an overall meta-analysis with aggregate data from the included trials for 
the primary endpoint. Heterogeneity in pooled outcomes was assessed with the χ² test and I² 
statistic. The hazard ratio (HR) and 95% confidence intervals (CI) for the primary endpoint were 
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calculated. 
Potential selection/publication bias was examined by constructing of a "funnel plot", in 
which the standard error (SE) of the ln HR was plotted against the HR for the primary endpoint.  A 
mathematical estimate of the asymmetry of this plot was obtained with a linear regression 
approach. 
 
 
Supplemental Results 
 
Study quality and risk of bias in included studies 
Supplementary Table I shows the quality assessment scales of studies in the ACCRUE 
database, that involved randomized intracoronary cell therapy in AMI.. The internal validity scales 
show that all studies allocated their patients adequately and that the treated and control groups were 
comparable; and all studies were conducted according to the intention-to-treat design. All trials 
reported a blinded analysis. External validity criteria were also adequate in all studies; they reported 
pre-specified patient characteristics, treatment regimens, levels of care, and outcome parameters. 
According to the pre-specified unified baseline and outcome parameters, the ACCRUE IPD meta-
analysis results are more generalizable than the results of previous meta-analyses, therefore, a 
higher level of external validity was achieved with this meta-analysis a priori, compared to an 
aggregate data meta-analysis with heterogeneous definitions. 
Sensitivity analyses were performed by removing one study at a time. This analysis 
demonstrated that no single study influenced the overall results; the effect estimates were consistent 
in magnitude and direction with the overall meta-analysis (data not shown).  
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Online Table I. Quality assessment scales for the randomized studies included in the 
“intracoronary cell therapy” arm of the ACCRUE database. 
 
Bias Selection 
  
Study 
Performance 
Detection/ 
Evaluation Attrition 
 
 
Adequate 
allocation? 
Method 
adequate for 
randomization? 
Groups 
similar at 
start of the 
study? 
Study patients/ 
staff blinded 
to study? 
Study analysis 
blinded to 
randomization
? 
Loss to 
follow-up 
(%)? 
Intention to 
treat 
analysis? 
Cedars yes yes yes yes yes 0% yes 
Aalst yes unclear yes yes yes 0%  
BONAMI yes yes yes no yes 0% yes 
REPAIR-
AMI yes yes yes yes yes 0% yes 
BOOST yes yes yes yes yes 0% yes 
LATE-TIME yes yes yes yes yes 0% yes 
ASTAMI yes yes yes no yes 0% yes 
REGENT yes yes yes no yes 0% yes 
SWISS-AMI yes yes yes no yes 0% yes 
TIME yes yes yes yes yes 0% yes 
SCAMI yes yes yes yes yes 0% yes 
FINCELL yes yes yes yes yes 0% yes 
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Online Table II.  Clinical end points using 9 supposed predictive factors 
 
 Hazard ratio lower 95% CI upper 95% CI p value 
MACCE     
Cell treatment 0.826 0.581 1.175 0.287 
Age 1.017 0.999 1.034 0.06 
Gender 1.035 0.663 1.616 0.88 
AMI anterior 1.257 0.764 2.069 0.369 
DM 0.922 0.591 1.439 0.72 
Hy 1.262 0.868 1.835 0.222 
HLP 1.032 0.719 1.484 0.863 
Pre-EDV 1.001 0.996 1.006 0.678 
Pre-EF 0.994 0.976 1.012 0.52 
     Death         
Cell treatment 0.544 0.171 1.729 0.302 
Age 1.087 1.017 1.161 0.014 
Gender 0.855 0.243 3.011 0.807 
AMI anterior 0.818 0.204 3.28 0.776 
DM 1.497 0.438 5.116 0.52 
Hy 1.21 0.335 4.369 0.772 
HLP 0.352 0.1 1.243 0.105 
Pre-EDV 0.992 0.977 1.008 0.325 
Pre-EF 0.938 0.889 0.989 0.019 
     Death/AMI/Stroke 
   Cell treatment 0.542 0.269 1.094 0.087 
Age 1.0 1.01 1.085 0.012 
Gender 1.106 0.461 2.653 0.821 
AMI anterior 1.514 0.492 4.658 0.47 
DM 1.036 0.457 2.346 0.933 
Hy 1.83 0.812 4.122 0.145 
HLP 0.713 0.35 1.455 0.353 
Pre-EDV 0.998 0.989 1.007 0.684 
Pre-EF 0.966 0.934 0.999 0.045 
     TVR         
Cell treatment 0.841 0.571 1.239 0.381 
Age 1.01 0.991 1.029 0.307 
Gender 0.988 0.604 1.615 0.96 
AMI anterior 1.216 0.707 2.09 0.479 
DM 0.871 0.526 1.44 0.59 
Hy 1.18 0.783 1.777 0.43 
HLP 1.159 0.775 1.732 0.473 
Pre-EDV 1.003 0.997 1.008 0.32 
Pre-EF 1.002 0.982 1.023 0.844 
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CI: confidence interval, MACCE: major adverse cardiac and cerebrovascular events, AMI: acute 
myocardial infarction, DM: diabetes mellitus, Hy: Hypertension, HLP: hyperlipidaemia, EDV: end-
diastolic volume, EF: ejection fraction, TVR: target vessel revascularization  
Significance if p<0.01 
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Online Table III. Detailed results of the Analysis of Covariance (ANCOVA).  
 
  
Changes 
in EDV 
 
Changes 
in ESV 
 
Changes in 
EF 
 
  
Mean 
value (SE) 
95% 
CI 
Mean 
value (SE) 
95% 
CI 
Mean value 
(SE) 
95% 
CI 
Cell therapy 
effect with 
male gender 
Cell therapy 
(n=511) 
12.4 (1.7) 8.6, 
16.3 
4.0 (1.6) 0.9, 
7.2 
4.0 (0.5) 3.1, 
5.0 
 Control 
(n=375) 
12.7 (2.5) 7.8, 
17.7 
4.1 (2.0) 0.0, 
8.2 
2.7 (0.6) 1.5, 
3.9 
        
Cell therapy 
effect with 
diabetes 
mellitus 
Cell therapy 
(n=85) 
16.0 (2.19) 11.7, 
20.3 
6.0 (1.8) 2.5, 
9.5 
3.16 (0.54) 2.1, 
4.22 
 Control 
(n=70) 
13.7 (2.45) 8.9, 
18.5 
4.9 (2.0) 0.98, 
8.8 
2.46 (0.6) 1.28, 
3.63 
        
Cell therapy 
effect with 
hypertension 
Cell therapy 
(n=303) 
15.1 (1.5) 12.1, 
18.0 
5.0 (1.2) 2.6, 
7.4 
3.6 (0.37) 2.8, 
4.3 
 Control 
(n=218) 
13.8 (1.8) 10.3, 
17.3 
4.7 (1.5) 1.8, 
7.5 
2.6 (0.4) 1.7, 
3.5 
        
Cell therapy 
effect with 
hyperlipid-
emia 
Cell therapy 
(n=316) 
17.6 (1.6) 14.5, 
20.7 
7.0 (1.3) 4.5, 
9.5 
3.15 (0.38) 2.4, 
3.9 
 Control 
(n=206) 
15.6 (1.9) 11.9, 
19.4 
6.4 (1.6) 3.3, 
9.4 
2.06 (0.46) 1.7, 
3.0 
        
Cell therapy 
effect with 
MRI  
Cell therapy 
(n=425) 
15.0 (1.62) 11.8, 
19.2 
4.3 (1.3) 1.7, 
6.9 
3.88 (0.4) 3.1, 
4.7 
 Control 
(n=240) 
13.8 (1.8) 10.2, 
17.3 
4.6 (1.5) 1.7, 
7.5 
2.56 (0.44) 1.7, 
3.4 
        
Cell therapy 
effect with 
age  
Cell therapy 
(n=624) 
23.8 (2.1)* 19.7, 
28.0 
11.2 (1.8) 7.6, 
14.8 
2.58 (0.924) 1.17, 
4.0 
 Control 
(n=440) 
14.4 (2.7) 9.1, 
19.6 
4.7 (2.3) 0.2, 
9.2 
2.23 (0.578) 1.09, 
3.36 
        
Cell therapy 
effect with 
Cell therapy 
(n=528) 
15.1 (2.1) 10.9, 
19.2 
3.4 (1.7) -0.0, 
6.7 
3.98 (0.52) 2.96, 
5.0 
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AMI anterior 
 Control 
(n=376) 
16.2 (2.6) 11.2, 
21.2 
5.4 (2.1) 1.3, 
9.5 
2.51 (0.64) 1.26, 
3.76 
        
Cell therapy 
effect with 
pre-EDV 
Cell therapy 
(n=624) 
16.5 (1.1) 14.2, 
18.7 
5.8 (0.98) 3.8, 
7.7 
3.4 (0.41) 2.6, 
4.3 
 Control 
(n=440) 
15.0 (1.3) 12.4, 
17.7 
5.5 (1.2) 3.2, 
7.8 
2.7 (0.49) 1.7, 
3.7 
Cell therapy 
effect with 
pre-EF 
Cell therapy 
(n=624) 
18.0 (1.3) 15.4, 
20.7 
7.04 (1.3) 4.5, 
9.5 
3.25 (0.48) 2.3, 
4.2 
 Control 
(n=440) 
16.3 (1.6) 13.2, 
19.5 
6.5 (1.5) 3.6, 
9.4 
2.49 (0.57) 1.4, 
3.6 
        
Cell 
treatment 
effect with 
time to cell 
therapy+ 
Cell therapy 
(n=624) 
13.5 (2.5) 8.6, 
18.3 
4.8 (2.0) 0.9, 
8.8 
2.7 (0.6) 1.6, 
3.9 
 Control 
(n=440) 
5.7 (4.3) -2.7, 
14.0 
-4.1 (3.5) -10.9, 
2.7 
3.5 (1.0) 1.4, 
5.5 
 
*p<0.01 
CI: confidence interval, EDV: end-diastolic volume, ESV: end-systolic volume, EF: ejection 
fraction, AMI: acute myocardial infarction, MRI: magnetic resonance imaging 
+Effect of the covariate time to cell therapy in cell therapy group or randomization/sham 
intervention in controls post AMI 
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Online Table IV. Mean values and SD of changes of ejection fraction (EF) in patients with 
intracoronary cell therapy post-AMI (n=486; mean number of patients: 26±16) and corresponding 
randomized controls (n=351; mean number of patients: 18±15) of 19 trials not participating in the 
ACCRUE database.  
 
Intracoronary 
cell injection 
FUP time Number 
of 
patients 
Changes in 
EF from 
baseline to 
FUP 
mean±SD 
Number 
of 
controls 
Changes in 
EF from 
baseline to 
FUP 
mean±SD 
Comments 
Ge29 6 mo 10 4.8 10 3.5 a 
Janssens30 4 mo 30 3.4±6.9 30 2.2±7.3  
Penicka31 4 mo 14 15.4 10 20.5 a 
Meluzin32 3 mo 44 2±1 and 5±1 22 2±1  
Suarez33 3 mo 10 20±8 10 6±10  
Noguira34 6 mo 14 6.7±5.5 6 2±11.5 b 
Plewka35 6 mo 38 10±9 18 5±8  
Cao36 6 mo 41 9.4 45 7.1 a 
Yao37 12 mo 27 NA 12 2.9±2 c 
Grajek38 6 and 12 mo 31 NA 14 NA a 
Piepoli39 12 mo 19 13.1±1.9 19 5.3±2  
Hirsch40 4 mo 67 3.8±7.4 60 4.0±5.8 d 
Turan41 3 mo 42 NA 20 NA  
Liepic42 6 mo 26 3±7.3 10 3.8±4.6  
Quyyumi43 6 mo 11 2.5±9 10 1±7.8 e 
Colombo44 12 mo 10 3±2.7 5  -3±3.9 f 
Chen45 3 mo 34 NA 35 NA a 
Houtgraaf46 6 mo 9 4.6 4 NA g 
Ruan47 6 mo 9 NA 11 NA a 
SD: standard deviation, AMI: acute myocardial infarction, FUP: follow-up, EF: ejection fraction, 
NA: data not available 
 
Comments: 
a: SD of changes at FUP were not reported; 
b: 10 patients received retrograde intravenous cell therapy; separate SD of changes were not 
reported; 
c: data of repeated intracoronary injection of cells 3 months post-AMI in Group B were pooled to 
the single injection Group A, but significant difference between Group A and B was reported. 
d: patients with intracoronary infusion of peripheral blood mononuclear cells are not included 
e: dose escalation study with 3 different doses 
f: data of bone marrow (Group A) and peripheral blood mononuclear cells (Group B) were pooled 
g: 3:1 randomization of 14 patients with 1 drop-out; SD of changes in cell therapy group not 
available, no data of changes in EF in control group 
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Online Figures 
 
Online Figure I. Overall meta-analysis of aggregate trial data in the included studies for the 
primary endpoint of major adverse cardiac events, defined as death, re-infarction, stroke and 
target vessel revascularization.   
Data in this table are based on the standard life table (first event per patient) computation. 
Individual papers contributing data to these tables may have used a different analysis plan and have 
reported their events differently. 
A. Meta-analysis of aggregate data 
B. Funel plot  
CI = confidence interval.  Aggregate data from Aalst trial were not generated owing to the lack of 
primary endpoint events in both arms and the small sample size. 
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Online Figure II. Kaplan-Meier survival and Cox regression analysis of freedom from death  
DM: Diabetes mellitus, CI = confidence interval 
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Online Figure III. Cumulative hazards of clinical events of all patients. No difference between 
the groups. 
A. Cumulative hazard of major adverse cardiac and cerebrovascular events (MACCE) 
B. Cumulative hazard of death  
C. Cumulative hazard of death / re-myocardial infarction (AMI) / stroke 
D. Cumulative hazard of target vessel revascularization (TVR) 
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Online Figure IV. Cumulative hazards of clinical events in subgroup of patients with >6 -12 
month control. No difference between the groups. 
 
A. Cumulative hazard of major adverse cardiac and cerebrovascular events (MACCE) 
B. Cumulative hazard of death  
C. Cumulative hazard of death / re-myocardial infarction (AMI) / stroke 
D. Cumulative hazard of target vessel revascularization (TVR) 
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Online Figure V. Cumulative hazards of clinical events in subgroup of patients with ≤ 6 
months control. No difference between the groups. 
 
A. Cumulative hazard of major adverse cardiac and cerebrovascular events (MACCE) 
B. Cumulative hazard of death  
C. Cumulative hazard of death / re-myocardial infarction (AMI)/ stroke 
D. Cumulative hazard of target vessel revascularization (TVR) 
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Online Figure VI. Correlation between the number of intracoronary delivered cells and 
changes in ejection fraction (DeltaEF) and end-diastolic volume (DeltaEDV) 
Lack of correlation was probably due to the large scatter in cell numbers. 
A. Correlation between number of injected cells and changes in left ventricular EF 
B. Correlation between number of injected cells and changes in left ventricular EDV 
C. Correlation between log number of injected cells and changes in left ventricular EF 
D. Correlation between log number of injected cells and changes in left ventricular EDV 
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